ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10,356 | +370.3% | 1,113,582 | +401.1% | 0.07% | +317.6% |
| Q1 2024 | $2,202 | +1137.1% | 222,222 | +562.5% | 0.02% | +750.0% |
| Q3 2023 | $178 | -81.8% | 33,545 | -49.2% | 0.00% | -85.7% |
| Q4 2022 | $977 | -99.9% | 65,995 | +40.3% | 0.01% | +16.7% |
| Q3 2022 | $899,000 | – | 47,055 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $305,003,000 | 24.46% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $115,121,000 | 6.52% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $16,462,000 | 5.28% |
| SECTORAL ASSET MANAGEMENT INC | 878,948 | $25,428,000 | 1.93% |
| Omega Fund Management, LLC | 623,836 | $18,048,000 | 1.71% |
| Orbimed Advisors | 6,073,850 | $175,716,000 | 1.64% |
| Altium Capital Management LP | 113,962 | $3,297,000 | 0.92% |
| Vivo Capital, LLC | 744,370 | $21,535,000 | 0.76% |
| Polar Capital Holdings Plc | 1,557,543 | $45,060,000 | 0.28% |
| Birchview Capital, LP | 9,000 | $260,000 | 0.15% |